{"name":"Septerna, Inc.","slug":"septerna-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SEP-479","genericName":"SEP-479","slug":"sep-479","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SEP-479","genericName":"SEP-479","slug":"sep-479","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPbVRyal96WUJITWlLQjJCWUI5TDlhanRxZE9DNGdEWVNQS1pkbmFPZU1RbmlrR0ZrR0hPYmFiQkkwT3J5Z2tjX0kyQmZ3aURyd094Rk9waHh1T0NxSUt0WlBUNms1VWhGdTVQUTlJdV96ZTBzWGhjVFZjcDVLRGtoU3hKdm1hUTVNNlhSQy1icFVOeWk3NGFnSm80MXVnWnRNV1NJMHBrVVF5Z3FxTkk3cFp5d1pCTlVMQXE4NVVMREhQM0dRMUduX0VjTTBVeVRjQVRUQ3RMZ1NNTWRmblBudjBSZG16QUdkLTlrc3VRUVNQLUIzQWk1eE11c25qcXpLVldaRjlhMUo?oc=5","date":"2026-03-12","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail","headline":"Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQb3VsbWVMZEFOVFNoQ0tsU2RHVDdPeFZJQ18tdkpYS3M2TGs2alRGdmpzQm01NENVUlFFaWlhS0YyVzlwYjBJcTNianlnd1JZaDh2alA3a0ttZElVVzg1N0lxZjlLSk5RX290bnRvLWtmXzNnbGhaTjJtYXluaFBnLTlZRXRzY3Yycmc?oc=5","date":"2026-02-10","type":"pipeline","source":"BioXconomy","summary":"Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy","headline":"Viatris Septerna BIO Takeda name new legal chiefs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPbHd4cjJoOUszVFMxdGczQU5ZRm1adWpsUXZZMWcxUUI0anFTSy0zTkhoWnFybkxRamtYaE5HOWxXWlJwNVBDVU14SVBZYXNZOFp1OGozVTNWTk5vcVRrMEVaLWsteVFrYXZrVWQ4ZTdUUjVJVUNFaEwtZ1gydXJhRWNzZThIWlRScmVDNndUejJGMmxVamJCQmRBSjI?oc=5","date":"2025-05-16","type":"pipeline","source":"seekingalpha.com","summary":"Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist - seekingalpha.com","headline":"Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOWVlxNXRsQjAwMUNJSVZfb1F1cE9UTjE2TExOT0xJZ0p5UUx6ZDFYRXZiUTJPZXY0SHlBRnVPdXFfeXVZQmxRZ0hHSGpiWnhkc3NzRlI0bGx5VG44aVl4TlFCVjJJSGVpRzF2cnNYdEViZEZWcWQwQXNzUUMwT3NWMUNlcDdHQUE2N1F4VmVpTE04WHZlRVdUY3dYRWkxYTJweWRYQXpFbXVMQzlIdkZ3Qm5BNmNmQlRwVVpMU2RsbXJVenI5S1QxNQ?oc=5","date":"2025-05-15","type":"deal","source":"WSJ","summary":"Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - WSJ","headline":"Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPT0wwOEN0OFJPc09mV2VUamxvNng2ek1mVVVMd05UWVQ2eV9YUlBINDU3TkVnVGdrZXpNZy1oV2JsekVtRE12ZVF3ZFBWakFoZ2ZhcTFpVy1KOGxXbVp1QUJYQW54aFY3b1NoRlFuR3NnY09DWnRtX3FPTkM3bmxGZ0JVclRKQV9DaDItbTdPNmFuUkl2dE0zWkZ0NA?oc=5","date":"2025-05-15","type":"pipeline","source":"Contract Pharma","summary":"Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma","headline":"Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQQzBSaDlOWUk2bV9QbWVFMjRaaHlYeFkwdjJHX1dvRU9qazVDRnhqNkdJLUFHNTdkNVVtcmhWOURaMjFEZHJ4TC00QkN3bXBfNkhnclEzMDNvakM5bjk1ZGtYRW55dFRhM3EzVm9XQS1ianVra3k0Q2t2X2J0eVF0NHNMemZfZFcyb0tF?oc=5","date":"2025-05-15","type":"deal","source":"Yahoo Finance","summary":"ETFs to Capitalize on the Novo Nordisk-Septerna Deal - Yahoo Finance","headline":"ETFs to Capitalize on the Novo Nordisk-Septerna Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNRlBCRjlSOVJhYmVscGlCdUtiR014c2pUY2dNRmFpdmxmbHFxTkI0eHEwRmlac2F0X3VZd0lDVWwxbW8xaTRYYjF6UGVGYmdzNjlhTjd0bTBHdFBkWDFpQjhXdFFiV0dXWXhnQndrSmNKdjZRY3hvM2g4Z3JpSEZfS29RV0lZN3BXckNMTnZ5Tk5BNFdlZ20xOWFYZlZ2eWRMNms0SllWWDBmcG1DTnFpSXVDcWpXNTExUTZEcGVPdmZWZTZodlVIdnVoOFVKMDZuTWU3ZEZkT1Y3Zw?oc=5","date":"2025-05-14","type":"deal","source":"Reuters","summary":"Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters","headline":"Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNdFNkV3M2ZF9PS0FhOGxHQ3JOam5SZzZyMjFXd1ZPVVNTbUdKVVR6MVBlZ0JOdi11SEZpRTlmQmptTkM1NFEzN3BESnNQZU1fSzRTcHZUTS1UV2FINGV0bXVJdDEySmNRWVhuRVgxbDB6d3U2VFA3VmJ6b0hNN2lscE0yemlKV3hIM29TUTY1a3pCWVRaU3c?oc=5","date":"2025-05-14","type":"pipeline","source":"BioPharma Dive","summary":"Novo to work with Septerna in hunt for oral obesity drugs - BioPharma Dive","headline":"Novo to work with Septerna in hunt for oral obesity drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQNDYtWEJ3ZncwR011ZERKVUhJNE9DVElaQS1MUUNIUWVNTG1qdzFmdDRHc1ZxWW1NelhNeUEwUElVRXlwM2hUZ3Q4MEpwWndXQ0dhNTZmeWpJZ29oRjVzUEpBOWZLdW85NEhyQ0pHMUFiT3A3WU81N0hobWN4YmtUS01rdEwyaWtQVjFTdTV0SDJhamt6dUhHNm5OaXZHS0dkaElEM3Jn?oc=5","date":"2025-05-14","type":"deal","source":"Fierce Biotech","summary":"Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs - Fierce Biotech","headline":"Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNbm1BMUFDcjA5OXctWWhoZkllMEROX1d6ZXNXNGx0YjR4LUpPcHEyRG1aR0wyYWRBTnc1ckMzTEFORDV3TkFjUlc2UE8zQjJsdlhBZENLY3NMcThtbnNxT3Z4bFZmb0xMeGV2UTdELXN2X29fVkRsYUQ4MHEtS0F2T3hQd3UtLTVhY0MzSmpBSU4zbzVJSS1NM1RNYzl3TGczYUF0UEsxUDRVUmNUMEF0b09rZmtiNlY3WUdLbTc1NA?oc=5","date":"2025-05-14","type":"deal","source":"MarketWatch","summary":"This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent - MarketWatch","headline":"This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOSm5mNW0wLWJQYkRpRmxHQVNQaGdYNDNDVG04dVhUNmpLQmh0NGNsUEx1UmtZSGpQbU5GN0o2ZDVtN3FZcU0yN28xN1h1V2Q3UnpzLXZ3Y2lxYUhaZndfYnRmYmZySllCNk5sRDlVNGY4Mi1yMkZiSkprZ1JQWW9HeFlNU0g5VmpY?oc=5","date":"2024-10-02","type":"pipeline","source":"SEC.gov","summary":"S-1 - SEC.gov","headline":"S-1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPSGpkWktvY1ZCTGxvX0gyYU9GNzFGYXQ2RGI5a0pqQkZhQnVSX0liTHJiRTBFQWZoTUlQMEJlSzhQUUdZWFVZcjZIR3NvMHF1emdmT05rNkpLY3lndVNMMnFOeHZXYjJtcllxNUpuNXVINFU4QlgtUkFBbnNuZHo5T2xERV91VUhRa0hyYjBtMm1mLXd1T0p5a1VtMHJpT2pueG9IQVBTczRLcFNRY29DblR0aHJNcUpZUmtwZ2lsZlNpaWJIXzVUZEgwUEhRejFFc2pHTlJGdkRHSU52Y0p0QVhGRjZISF9kdy1EVmZkMDMxY0QtbmJRM0RwaEtsaFhKSkZ2TjNZNGNvZkk?oc=5","date":"2024-09-25","type":"pipeline","source":"businesswire.com","summary":"Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - businesswire.com","headline":"Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Rol","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}